Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFCAP.L Regulatory News (FCAP)

  • There is currently no data for FCAP

Trading Update

27 Feb 2020 07:00

RNS Number : 2694E
finnCap Group PLC
27 February 2020
 

27 February 2020

 

finnCap Group plc

("finnCap" or the "Group")

 

Trading Update

The Group provides the following update on trading for the year ending 31 March 2020.

Throughout the year the equity capital markets division has continued to complete a variety of deals and has won a further 19 retained corporate clients, offset by client churn largely from delistings or acquisitions. The Board expects that the trading performance in the equity capital markets division will be in line with that recorded in the first half of this financial year.

In the M&A division the Board noted at the time of the interims that the outturn was reliant on a number of higher value transactions. Since then the timetable for these deals has lengthened, and the Board has now concluded that the trading performance in this division will be below that seen in the first half of the year.

Whilst deals have been slow to close in the M&A division, it has continued to sign up deal retainers during the period and since 1 April 2019 has signed 36 mandates and generated deal retainers of £1.2m. The level of deal retainers gives the Board confidence in the outlook for the division and the delayed transactions are expected to benefit the first quarter of FY21.

Overall the Board expects that the Group's trading performance for the second half of the financial year will be broadly breakeven, and that the Group will trade profitably for the financial year.

The Board has recently reduced the Group's operating expenses to ensure that the fixed costs of the business in FY21 will be broadly the same as in the current financial year.

The combination of the reduction in costs, the expectation that the M&A division will benefit from closing the larger deals delayed from the second half of the current financial year, and a continuing return to more normal market conditions in the equity capital market division, means that the Board expects the Group's trading performance in the first quarter of FY21 will show an improvement on its performance in the second half of the current financial year. The Board does however note the continued spread of COVID-19 and its effect on global capital markets and will closely monitor the situation.

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

Contacts

finnCap Group plc Tel: +44 (0) 20 7220 0500

Sam Smith, Chief Executive Officer investor.relations@finncap.com

 

Tom Hayward, Chief Financial Officer

 

Grant Thornton (Nominated Adviser)  Tel: +44 (0) 20 7383 5100

Philip Secrett/Samantha Harrison/Seamus Fricker

 

finnCap Ltd (Broker) Tel: +44 (0) 20 7220 0500

Rhys Williams

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUNRRRROUUUUR
Date   Source Headline
19th Oct 20227:15 amRNSRule 2.9 Announcement
18th Oct 20222:58 pmEQSForm 8.3 - Maitland Institutional Services Limited: Re finnCap plc
18th Oct 20227:00 amRNSResponse to offer speculation
3rd Oct 20227:00 amRNSTotal Voting Rights
28th Sep 20227:00 amRNSDirectorate Change
15th Sep 202211:16 amRNSResult of AGM
15th Sep 20227:00 amRNSAGM Trading Update
1st Sep 20227:00 amRNSCEO Transition Completed
1st Sep 20227:00 amRNSTotal Voting Rights
5th Aug 20227:00 amRNSDividend Declaration, Annual Report & AGM Notice
1st Aug 20227:00 amRNSTotal Voting Rights
14th Jul 20227:00 amRNSResults for year ended 31 March 2022
8th Jul 20227:00 amRNSAppointment of Executive Directors
1st Jul 20227:00 amRNSTotal Voting Rights
21st Jun 20227:00 amRNSProposed New CEO and appointment of new Directors
1st Jun 20227:00 amRNSBlock Admission Return and Total Voting Rights
16th May 20227:00 amRNSDirectorate Change
29th Apr 20227:00 amRNSTotal Voting Rights
28th Apr 20227:00 amRNSBuilding a leading advisory business
14th Apr 20227:23 amRNSFY22 Unaudited Revenue
1st Apr 20227:00 amRNSTotal Voting Rights
10th Mar 20227:00 amRNSTrading Update
1st Mar 20227:00 amRNSTotal Voting Rights
8th Feb 20229:18 amRNSDirector Dealing
1st Feb 20227:00 amRNSTotal Voting Rights
28th Jan 202210:22 amRNSHolding(s) in Company
28th Jan 202210:21 amRNSHolding(s) in Company
26th Jan 20227:00 amRNSOption Exercise, Dealing Amendment and TVR
25th Jan 20227:00 amRNSAppointment of Non-Executive Director
31st Dec 20217:00 amRNSTotal Voting Rights
9th Dec 20215:25 pmRNSHolding(s) in Company
8th Dec 20214:04 pmRNSCOVID Option Exercises and EBT Holdings in Company
1st Dec 20217:00 amRNSBlock Admission Return and Total Voting Rights
18th Nov 20217:00 amRNSInterim Results and Dividend
2nd Nov 20217:00 amRNSNotice of Interims and Investor Presentation
1st Nov 20217:00 amRNSTotal Voting Rights
19th Oct 202111:01 amRNSHolding(s) in Company
4th Oct 20217:00 amRNSH1 22 Unaudited Revenues – strong growth on H1 21
1st Oct 20217:00 amRNSTotal Voting Rights
24th Sep 20217:00 amRNSExercise of Options and Total Voting Rights
23rd Sep 202111:21 amRNSResult of AGM
23rd Sep 20217:00 amRNSAGM Trading Statement
15th Sep 20219:51 amRNSAGM Update
1st Sep 20217:00 amRNSTotal Voting Rights
30th Jul 20217:00 amRNSTotal Voting Rights
22nd Jul 20217:00 amRNSSecond Interim Dividend
7th Jul 202110:00 amRNSAnnual Report and Annual General Meeting Notice
6th Jul 20217:00 amRNSDirector Dealing, Option Exercise and TVR
1st Jul 20217:00 amRNSPreliminary results - year ended 31 March 2021
1st Jul 20217:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.